Sympathomimetic agents should be used with caution in patients with glaucoma, prostatic hypertrophy or bladder neck obstruction, cardiovascular disease, increased intraocular pressure or diabetes mellitus.
Sympathomimetics should be used with caution in patients receiving digitalis.
Sympathomimetics may cause CNS stimulation, excitability, convulsions and/or cardiovascular collapse with accompanying hypotension.
Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; an initial dose of 1 tab every other day is recommended.
Patients who have a history of difficulty in swallowing tablets, or have had known upper gastrointestinal narrowing or abnormal esophageal peristalsis should not use this product.
Drug Abuse and Dependence: No data are available to indicate that abuse or dependency occurs with loratadine. Like other CNS stimulants, pseudoephedrine sulfate has a potential for abuse, and increased doses may ultimately produce toxicity. Depression may follow rapid withdrawal.
Use in pregnancy & lactation: Safe use of Clarinase 24 Hr Extended Release during pregnancy has not been established. Therefore, the product should be used only if the potential benefit justifies the potential risk to the fetus.
Since loratadine and pseudoephedrine sulfate are excreted in breast milk, a decision should be made whether to discontinue nursing or to discontinue the use of Clarinase 24 Hr Extended Release.
Use in children: Safety and efficacy of Clarinase 24 Hr Extended Release in children <12 years of age have not been established.
Use in the elderly: In patients ≥60 years, sympathomimetics also are most likely to cause adverse reactions eg, confusion, hallucination, convulsions, CNS depression and death. Consequently, caution should be exercised when administering a long-acting formulation to elderly patients.